Testing of serum Kisspeptin and DLK1 levels in Central Precocious Puberty at Diagnosis and After Pubertal Suppression

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210901002

Enrollment

Registered

2021-09-01

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central precocious puberty Precocious puberty Kisspeptin DLK1 pubertal suppression

Interventions

Girls age 6-8 years who diagnosed with central precocious puberty ,Age-matched pre-pubertal girls who is previously healthy.

Diagnostic,Diagnostic

CPP girls,Control group

Eligibility

Sex/Gender

Female

Age

6 Years to 8 Years

Inclusion criteria

Inclusion criteria: 1. Girls 2. Diagnostic criteria of CPP 2.1 Girls with breast Tanner II before the age of 8 years 2.2 Peak LH from GnRH stimulation test more than 6 IU/L or baseline LH more than 0.3 IU/L 2.3 Bone age advancement more than one year

Exclusion criteria

Exclusion criteria: Congenital adrenal hyperplasia Chronic diseases Cerebral palsy Post-insult: hydrocephalus, CNS infection, radiotherapy, chemotherapy Medications: External hormone use, anti-androgen drugs

Design outcomes

Primary

Measure	Time frame
Kisspeptin At diagnosis of CPP and 6 months after treatment of CPP ELISA,DLK1 At diagnosis of CPP and 6 months after treatment of CPP ELISA	—

Secondary

Measure	Time frame
characteristics of CPP girls Baseline and after treatment of CPP Demographic data,Correlation of serum Kisspeptin and DLK1 levles At at diagnosis of CPP and 6 months after treatment Correlation	—

Countries

Thailand

Contacts

Public ContactKhomsak Srilanchakorn

Department of Pediatrics, Faculty of Medicine, Chulalongkorn University

Khomsak_s@hotmail.com0816777460

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026